Published in Arch Dermatol on March 01, 2006
Women's dermatologic diseases, health care delivery, and socioeconomic barriers. Arch Dermatol (2006) 1.94
Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend (2012) 1.41
Estimation of multiple transmission rates for epidemics in heterogeneous populations. Proc Natl Acad Sci U S A (2007) 1.25
Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses. Proc Natl Acad Sci U S A (2014) 1.06
Understanding the gender disparity in HIV infection across countries in sub-Saharan Africa: evidence from the Demographic and Health Surveys. Sociol Health Illn (2011) 0.96
X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am J Hum Genet (2009) 0.92
Chlamydia prevalence in the general population: is there a sex difference? a systematic review. BMC Infect Dis (2013) 0.86
Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother (2008) 0.85
Associations between psychosocial factors and incidence of sexually transmitted disease among South African adolescents. Sex Transm Dis (2015) 0.77
Polymerase Chain Reaction as a Diagnostic Tool for Six Sexually Transmitted Infections - Preliminary Results. Clujul Med (2015) 0.75
Disgust versus Lust: Exploring the Interactions of Disgust and Fear with Sexual Arousal in Women. PLoS One (2015) 0.75
Anatomical and hormonal influences on women's dermatologic health. JAMA (2006) 0.75
An evolutionary behaviorist perspective on orgasm. Socioaffect Neurosci Psychol (2016) 0.75
The burden of HIV on Tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for Tuberculosis control. BMC Infect Dis (2017) 0.75
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis (2008) 3.52
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol (2005) 2.08
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol (2006) 1.69
Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet (2002) 1.67
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol (2011) 1.51
Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res (2004) 1.50
Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol (2011) 1.46
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect (2004) 1.42
Tropical dermatology: viral tropical diseases. J Am Acad Dermatol (2003) 1.40
MD/PhDs are more likely than MDs to choose a career in academic dermatology. Dermatol Online J (2008) 1.39
An HIV-Positive Male with a Herald Plaque. Clin Infect Dis (2011) 1.38
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
Tropical dermatology: Venomous arthropods and human skin: Part I. Insecta. J Am Acad Dermatol (2012) 1.35
Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett (2006) 1.34
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol (2013) 1.25
The expanding spectrum of eschar-associated rickettsioses in the United States. Arch Dermatol (2010) 1.24
Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol (2008) 1.24
Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol (2008) 1.24
Cutaneous metastasis to the chest wall from prostate cancer. Int J Dermatol (2006) 1.20
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis (2011) 1.17
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
Dermatology residency program characteristics that correlate with graduates selecting an academic dermatology career. Arch Dermatol (2006) 1.14
Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine (2005) 1.09
Herpes simplex viruses 1 and 2. Dermatol Clin (2002) 1.07
Tropical dermatology: marine and aquatic dermatology. J Am Acad Dermatol (2009) 1.07
Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol (2007) 1.05
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine (2010) 1.04
Detection of human papillomavirus in cutaneous clear cell squamous cell carcinoma in situ: viral-associated oncogenesis may contribute to the development of this pathologic variant of skin cancer. J Cutan Pathol (2008) 1.04
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol (2009) 1.03
Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol (2004) 1.01
Spectrum of ocular allergy. Curr Opin Allergy Clin Immunol (2002) 0.99
Ranking the dermatology programs based on measurements of academic achievement. Dermatol Online J (2007) 0.98
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract (2006) 0.98
Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. Transfusion (2008) 0.98
Subcutaneous fungal infections. Dermatol Ther (2004) 0.98
Managing herpes zoster in immunocompromised patients. Herpes (2007) 0.96
Human papillomavirus: a review. Dermatol Clin (2002) 0.96
Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. J Infect Dis (2011) 0.96
Biological and clinical basis for molecular studies of interferons. Methods Mol Med (2005) 0.95
Therapy of nontuberculous mycobacterial infections. Dermatol Ther (2004) 0.93
Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett (2003) 0.93
Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther (2003) 0.92
Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg (2005) 0.91
An update on the clinical management of cutaneous molluscum contagiosum. Skin Therapy Lett (2014) 0.90
Rapidly enlarging growth of the proximal nail fold. Dermatol Surg (2003) 0.90
Tropical dermatology: Venomous arthropods and human skin: Part II. Diplopoda, Chilopoda, and Arachnida. J Am Acad Dermatol (2012) 0.90
Selected sexually transmitted diseases and their relationship to HIV. Clin Dermatol (2004) 0.90
Molecular diagnosis of infectious diseases in dermatology. J Am Acad Dermatol (2005) 0.90
Trends in enzyme therapy for phenylketonuria. Mol Ther (2004) 0.89
Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol (2006) 0.89
Antibiotic overuse and resistance in dermatology. Dermatol Ther (2012) 0.89
Regulation of adrenal glucocorticoid synthesis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona fasciculata. Brain Behav Immun (2005) 0.88
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res (2004) 0.87
Seborrheic Keratosis-like lesions in patients with epidermodysplasia verruciformis. J Dermatol (2003) 0.87
Demographic, behavioral, and knowledge factors associated with herpes simplex virus type 2 infection among men whose current female partner has genital herpes. Sex Transm Dis (2005) 0.86
Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist (2012) 0.86
Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen (2003) 0.86
Viremia in acute herpes zoster. J Infect Dis (2009) 0.86
Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy. Biochem Biophys Res Commun (2006) 0.85
Human papillomaviruses vaccine: a dermatologic perspective. Indian J Dermatol Venereol Leprol (2010) 0.85
The cutaneous manifestations of HIV infection. Dermatol Clin (2002) 0.85
Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother (2013) 0.85
Physiological role of N-acetylaspartate: contribution to myelinogenesis. Adv Exp Med Biol (2006) 0.85
Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol (2010) 0.85
Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). Antiviral Res (2002) 0.84
Therapy of cutaneous human Papillomavirus infections. Dermatol Ther (2004) 0.84
Suppression of growth by all-trans retinoic acid requires prolonged induction of interferon regulatory factor 1 in cervical squamous carcinoma (SiHa) cells. Clin Diagn Lab Immunol (2002) 0.84
Clinical, histopathological and virological findings in patients with focal epithelial hyperplasia from Colombia. Int J Dermatol (2005) 0.84
Family history and herpes zoster risk in the era of shingles vaccination. J Clin Virol (2011) 0.83
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol (2010) 0.83
Association of p53 arginine polymorphism with skin cancer. Int J Dermatol (2004) 0.83
An unusual presentation of two simultaneous primary melanomas. Int J Dermatol (2006) 0.83
Evidence for endogenous interleukin-10 during nociception. J Neuroimmunol (2003) 0.83
Acquired and genetic susceptibility to cervical cancer. Mutat Res (2003) 0.83
Comprehensive analysis of genetic polymorphisms in the interleukin-10 promoter: implications for immune regulation in specific ethnic populations. Genet Test (2004) 0.83
HLA-DQB1 and cervical cancer in Venezuelan women. Gynecol Oncol (2005) 0.83
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs. J Am Acad Dermatol (2002) 0.83
Specific detection of trichodysplasia spinulosa–associated polyomavirus DNA in skin and renal allograft tissues in a patient with trichodysplasia spinulosa. Arch Dermatol (2012) 0.83
Images in clinical medicine. Podoconiosis. N Engl J Med (2011) 0.82
Rickettsial infections around the world, part 1: pathophysiology and the spotted fever group. J Cutan Med Surg (2005) 0.82
Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. J Am Acad Dermatol (2004) 0.82
Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease. Brain Res Dev Brain Res (2004) 0.82
Polymorphisms of the interleukin 10 gene promoter in patients from Brazil with epidermodysplasia verruciformis. J Am Acad Dermatol (2003) 0.82
Homozygosity for the c.917A→T (p.N306l) polymorphism in the EVER2/TMC8 gene of two sisters with epidermodysplasia verruciformis Lewandowsky-Lutz originally described by Wilhelm Lutz. Dermatology (2010) 0.82
Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization. Dermatol Online J (2012) 0.82
Clinical characteristics and awareness of skin cancer in Hispanic patients. Dermatol Online J (2013) 0.82
Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol (2008) 0.82
Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol (2014) 0.82
All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. Anticancer Res (2004) 0.81